Eighthly, by dampening chronic inflammation using potent anti-inflammatory agents such as JAK2 inhibitor treatment and statins, it is anticipated that the rate of thromboembolic events will likely decline, since chronic inflammation per se carries an increased risk of thrombosis due to several factors as outlined above (leukocytosis, thrombocytosis, and in vivo leukocyte-platelet and endothelial activation). This evidence concerns the gene JAK2 and Venous thrombosis.